Skip to content

Financing Cash Flow at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$813.17M+2,197%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-$52.8M-3,386%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$1.39M+253%
XER
Xeris Biopharma Holdings, Inc.XERS
-$8.84M-182%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$138.78M
PVL
Palvella TherapeuticsPVLA
$214.73M+17,964%

Other financials

Income statement

See full
Operating income-$2.0M+61.2%
Net income-$2.5M+49.6%
EPS (diluted)-$0.05+54.5%

Balance sheet

See full
Cash & equivalents$3.1M+1,132%
Total equity$2.5M-41.5%
Total assets$3.5M

Cash flow

See full
Operating cash flow-$2.1M-191%

Valuation

See full
Market cap$132.59M-87.6%

Returns & leverage

See full
Return on equity-1,209.8%
Current ratio3.5×

Where this comes from

Reported directly by Polaryx Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Polaryx Therapeutics, Inc. ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Polaryx Therapeutics, Inc. 's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Polaryx Therapeutics, Inc. 's financing cash flow?
Polaryx Therapeutics, Inc. (PLYX) reported financing cash flow of $250K in Q1 2025.
How has Polaryx Therapeutics, Inc. 's financing cash flow changed year-over-year?
Polaryx Therapeutics, Inc. 's financing cash flow decreased by 86.1% year-over-year, from $1.8M to $250K.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.